Welcome to the third newsletter for people taking part in REVEAL

Thank you for your continuing participation in the REVEAL study. Your support over the last few years has been invaluable to us.

REVEAL has followed the health of more than 30,000 people in 10 countries to study the effects of taking anacetrapib for the prevention of circulatory diseases such as heart attacks and strokes.

In late 2016 your clinic visits for this important study will be coming to an end.

We expect to report our findings in 2017, both at a medical conference and in a medical journal. Where possible we will send you a summary of the results, but you will also be able to see these summary results on our website.

REVEAL is uniquely positioned to answer questions about the contribution of good and bad cholesterol on the risk of serious cardiovascular diseases.

You have all volunteered to give your time and commitment to the study to allow us to answer these questions and make this possible.

Thank you! We couldn’t do this without your help.

With very best wishes,

Martin Landray and Louise Bowman
REVEAL Principal Investigators,
University of Oxford

Final follow-up visits

We will be starting to see you for your final visits from July 2016. It is really important that you come to the visit if possible, even if you are not taking the study tablets any more.

Also, if your most recent follow-up has been by telephone we would still really like to see you in clinic for the last time.

Please note that the appointment will take slightly longer than usual so that the nurse can do some additional tests.

You will be asked to provide a urine sample and we would like to make some physical measurements, including your neck, waist and hip circumference and your weight.

There will also be a short questionnaire asking you to tell us about your mood and some brief memory tests.

If you are still taking the study tablets, please continue with them until your final visit. Please bring any unused study tablets with you. At the end of your final visit you will be asked to stop taking the REVEAL study tablets.

If you are taking the study atorvastatin, you will need to ask your own doctor to supply your statin therapy after your final visit.

We would recommend that the statin prescription is of similar strength and dose as the study atorvastatin that you have been taking during REVEAL.

Ideally, you would start taking the statin from your own doctor as soon as you have taken your last dose of study medication, so you may wish to make an appointment with your doctor just before your final REVEAL visit.

And finally, our study nurses and doctors will want to say farewell to you. We have loved seeing you in clinics and will be sad to say goodbye!
Keeping on track until the end

In the REVEAL trial we are aiming to find out whether anacetrapib can help to improve the lives of millions of people who are at risk of heart attacks and strokes. We certainly hope this will be the case, but we can by no means be certain.

We can only answer this important medical question confidently if as many of you as possible keep coming into clinic. If you are not able to come to clinic we still want to know how you are doing, even if you are no longer able to take the tablets.

At a recent count, approximately 98% of our 30,000 participants had been followed up, either by coming in to clinic or via a telephone call from the study nurse.

Meanwhile, nearly 89% of you are still taking the study medications. These numbers are hugely impressive and they are testament to your commitment.

However we’ve still got a little way to go!

By continuing to come to clinic every six months and taking the tablets until your final study visit we can all ensure that the results are as reliable as possible.

Don’t forget to let the clinic know if you change your address or telephone number so that the staff can keep in touch.

If you have an email address please give that to your clinic staff too – it is a great way to send you important information about the study.

A reminder of drugs that should generally NOT be taken with one or other of the study treatments

If you are taking one of the following drugs, please contact your study nurse or doctor or ring the Freephone service on 0800 585 323 for further advice.

1. For lowering cholesterol
   Statins: if your own doctors wish to change the atorvastatin dose you are receiving in REVEAL or change to a different statin please contact your study clinic first.

   Fibrates:
   Bezafibrate (Bezalip, Bezalip Mono, Bezagen XL, Fibrazate XL, Liparol XL, Zimbral XL)
   Cipofibrate (Modalim)
   Fenofibrate (Fenogal, Lipantil, Lipantil Micro, Supralip)
   Gemfibrozil (Lopid)

   High dose niacin (more than 100 mg per day):
   Nicotinic acid (Niaspan)
   Acipimox (Olabetam)

2. Antibiotics
   Erythromycin (Arpimycin, Erymax, Erymin, Erythrocin, Erythroped, Ilosone, Tiloryth)
   Clarithromycin (Biaxin, Claripen, Clarixin, Crixan, Fromilid, Klabax, Klacid, Klaricid, Vikrol)
   Telithromycin (Ketek)
   Daptomycin (Cubicin)

3. Antifungals
   (excluding creams or eye/ear drops)
   Itraconazole (Sporanox)
   Posaconazole (Nofa-fil)
   If you are taking one of the antibiotics or antifungal medicines listed above, you would be able to re-start the study treatments once you have completed the course of tablets.

4. Protease Inhibitors
   Atazanavir (Reyataz)
   Fosamprenavir (Telzir)
   Lopinavir (Kaletra)
   Darunavir (Prezista)
   Nelfinavir (Viracept)
   Ritonavir (Norvir)
   Saquinavir (Invirase, Fortovase)
   Tipranavir (Aptivus)
   Indinavir (Crixivan)

5. Other
   Ciclosporin (Neoral, Sandimmun, SandCya)
   Fusidic acid (excluding creams or eye/ear drops)
   Nefazodone (Serzone, Nefadan)

We hope you have found this newsletter interesting and helpful. If you have any feedback, please write or email to the following address.

REVEAL Central Coordinating Office
CTSU, Nuffield Department of Population Health, University of Oxford
Richard Doll Building, Old Road Campus, OXFORD, OX3 7LF, UK
Tel: 0800 585 323 (toll free from UK), +44 1865 743 882 (from outside UK)
Email: ccoreveal@cts.ox.ac.uk